Med-tech firm ANGLE PLC (LON:AGL, OTCQX:ANPCY) has uncovered another potential use of its liquid biopsy system building on the success it has already had isolating and identifying tell-tale signs of breast, head and neck cancers.
The results of a study to be presented to the prestigious American Society of Clinical Oncology in Chicago point to a potential use in the colorectal cancer.
Researchers at the University of Texas MD Anderson Cancer Center used ANGLE’s Parsortix system to harvest circulating tumour cells in patients with the disease.
What they were looking for meEGFR biomarkers within the cells. It is thought patients with said genetic characteristic respond less well to a form of treatment called an EGFR inhibitor.
The MD Anderson study found those with the markers had shorter progression-free survival rates than those without.
Growing body of evidence
"This colorectal cancer study adds to the body of evidence driving adoption of Parsortix in the fast growing liquid biopsy market,” said ANGLE chief executive Andrew Newland.
“The ability to assess the patient's likely response to a particular drug as a companion diagnostic is a key element in the drive to provide precision medicine for patients saving money and improving treatment."
ANGLE invented and developed the revolutionary Parsortix system, which can detect the early signs of cancer from small samples of blood by identifying the presence of tiny circulating tumour cells.
Parsortix is the centre-piece in two clinical studies in ovarian cancer: ANG-001 in Europe (200 patients) and ANG-003 in the United States (200 patients).
The headline data following a statistical evaluation of the predictive power of the device should be available sometime this quarter, the firm said last month.
ANG-002, assessing Parsortix’s role in detecting metastatic breast cancer, remains on track for completion by the end of the calendar year, it added.